AstraZeneca Expands Coppell Manufacturing Site to Double Production of Lokelma
Pharmaceutical company AstraZeneca has expanded its Coppell manufacturing site with the aim of doubling production of the drug Lokelma. The expansion is a significant investment in the site, which is the sole manufacturer of Lokelma, a medication used to treat a condition called hyperkalemia.
Hyperkalemia is a relatively rare but life-threatening condition characterized by high levels of potassium in the blood. Lokelma is distributed from the Coppell site to more than 50 countries, including the U.S., making it a crucial medication for patients around the world.
About the Expansion
AstraZeneca invested $445 million in the expansion, according to a company announcement. The expansion includes a new 9,000-square-foot building, new manufacturing lines, and administrative space. This significant investment demonstrates the company’s commitment to increasing production of Lokelma and meeting the growing demand for the medication.
The expansion is expected to have a positive impact on the local economy, with the creation of new jobs and opportunities for skilled workers. The Coppell site currently employs about 250 people, and the expansion will create about 30 new skilled manufacturing and laboratory jobs.
Ribbon Cutting Ceremony
Coppell city leaders and Texas state representatives joined employees and executives from AstraZeneca as they hosted a ribbon cutting ceremony to celebrate the expansion of their manufacturing site in Coppell on October 15, 2025.
Steve Hamm / Special Contributor
Construction and Job Creation
AstraZeneca unveiled the expanded space Wednesday. Company spokesperson Lauren-Jei McCarthy said major construction for the building space is already completed. Two new manufacturing components are scheduled to come on-line in 2026.
The expansion will create new opportunities for skilled workers in the area, with about 30 new jobs being created. This is a significant boost to the local economy, and demonstrates AstraZeneca’s commitment to investing in the community.
Stay Up-to-Date with the Latest News
Business Briefing
Conclusion
The expansion of AstraZeneca’s Coppell manufacturing site is a significant investment in the production of Lokelma, a crucial medication for patients with hyperkalemia. The expansion will double production of the drug, creating new opportunities for skilled workers and boosting the local economy. With the creation of new jobs and the investment in the community, AstraZeneca is demonstrating its commitment to the area and to the production of life-saving medications.
Frequently Asked Questions
What is Lokelma used to treat?
Lokelma is used to treat a condition called hyperkalemia, which is characterized by high levels of potassium in the blood. It is a relatively rare but life-threatening condition that requires immediate medical attention.
Where is Lokelma distributed from?
Lokelma is distributed from the Coppell site to more than 50 countries, including the U.S.
How much did AstraZeneca invest in the expansion?
AstraZeneca invested $445 million in the expansion of the Coppell manufacturing site.
How many new jobs will be created as a result of the expansion?
The expansion will create about 30 new skilled manufacturing and laboratory jobs.
When will the new manufacturing components come on-line?
Two new manufacturing components are scheduled to come on-line in 2026.
